December 4, 2023

WeightWatchers’ stock soared Tuesday just after the corporation mentioned it is getting into the prescription drug pounds loss organization with the acquisition of Sequence.

Sequence is a telehealth company that offers users obtain to medicines applied to treat diabetes and weight problems underneath the model names such as Ozempic, Wegovy and Trulicity. The medicine all operate by the similar system: They cause the launch of insulin, block sugar generation in the liver and suppress appetite.

WeightWatchers features subscribers food plans with the intention of losing surplus bodyweight. With the acquisition of Sequence, it is tapping into a purple-sizzling market place for prescription medication that tackle being overweight, and broadening what it gives to clients.

Shares of WW Worldwide Inc. shut Tuesday up 79%.

“It is our obligation, as the trusted leader in weight administration, to aid all those fascinated in checking out if prescription drugs are correct for them,” claimed CEO Sima Sistani claimed in a geared up assertion late Monday.

Ozempic and Wegovy are different versions of the exact same drug, regarded as semaglutide. They’re both equally offered as when-weekly injections. Ozempic is authorised only to deal with diabetic issues, though it has been increasingly recommended for off-label use. Wegovy was accepted in 2021 to handle being overweight in grownups, and late last calendar year to deal with the condition in adolescents 12 and more mature.

In a scientific trial, grownups who utilised Wegovy dropped about 15% of their initial entire body weight, when teens shed somewhat a lot more. For ideal outcomes, the drugs really should be put together with diet program and physical exercise, professionals say. Trulicity is a various drug, dulaglutide, used to address diabetic issues in older people and children ages 10 and older. It’s not authorised to treat weight problems.

The off-label use of semaglutide, spurred by social media posts, led to a shortage of the drug for most of final year. Novo Nordisk explained supplies are getting replenished, but a lot of diabetes sufferers continue to report difficulties accessing the drugs they require.

The two Ozempic and Wegovy can lead to attainable side results, the business stories. They include probable thyroid cancer, pancreatitis, kidney and gallbladder troubles. The most frequent side consequences are nausea, vomiting, diarrhea, abdomen suffering and constipation.

Weight problems prevalence rose from 30.5% from the 1999-2000 time period to 41.9% for 2017 by way of March 2020, according to the Centers for Condition Handle and Avoidance. The prevalence of critical weight problems surged from 4.7% to 9.2% for the similar periods.

The believed yearly medical price tag of obesity in the U.S. was practically $173 billion in 2019 pounds, in accordance to the CDC. Once-a-year health-related prices for older people who had obesity had been $1,861 larger than health care prices for folks with wholesome weight.

“This deal brings accessibility to prescription drug methods for pounds decline to WW’s historic focus on behavior modification model,” wrote UBS analyst Michael Lasser. “This is a significant improve in the business enterprise. Whilst the deal could carry significant upside, it also carries sizable threats.”

Lasser claimed that WW’s company has been disrupted in excess of the final various years and is now making an attempt to choose large ways to system right.

“We feel it will consider time to see if this motion really creates a modify in the firm’s fortunes,” he said.

WW Global, based in New York, will spend $106 million for Sequence, which served about 24,000 associates throughout the U.S. as of February, with annual earnings of about $25 million.

The acquisition is expected to shut in the fiscal next quarter.


Affiliated Push Wellbeing Author JoNel Aleccia contributed to this report.

Michelle Chapman, The Linked Press


Leave a Reply

Your email address will not be published. Required fields are marked *